On May 13, 2025, Needham analyst Mike Matson reiterated his "Buy" rating for OncoCyte (OCX, Financial), a biopharmaceutical company. The rating aligns with his previous analysis, maintaining his confidence in the company's market potential.
Needham maintains the price target for OncoCyte (OCX, Financial) at USD 4.25, unchanged from previous assessments. This reflects continued optimism about the company's performance and future prospects as per the analyst's evaluation.
The reiteration of the "Buy" rating and consistent price target indicate a stable outlook for OncoCyte (OCX, Financial) in the coming period, with no significant price target percentage change noted in the report.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 2 analysts, the average target price for OncoCyte Corp (OCX, Financial) is $4.50 with a high estimate of $5.00 and a low estimate of $4.00. The average target implies an upside of 60.14% from the current price of $2.81. More detailed estimate data can be found on the OncoCyte Corp (OCX) Forecast page.
Based on the consensus recommendation from 4 brokerage firms, OncoCyte Corp's (OCX, Financial) average brokerage recommendation is currently 2.5, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for OncoCyte Corp (OCX, Financial) in one year is $2.50, suggesting a downside of 11.03% from the current price of $2.81. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the OncoCyte Corp (OCX) Summary page.
